KITLG Products By Gene Name

455-MC) stimulates prolif-eration in the TF-1 human erythro-leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse SCF/c-kit Ligand (25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse SCF/c-kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA). The ND₅₀ is typically 0.3-0.6 µg/mL." class="big_lightbox"> 455-MC) stimulates prolif-eration in the TF-1 human erythro-leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse SCF/c-kit Ligand (25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse SCF/c-kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA). The ND₅₀ is typically 0.3-0.6 µg/mL." alt="Recombinant Mouse SCF/c-kit Ligand (Catalog # 455-MC) stimulates prolif-eration in the TF-1 human erythro-leukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse SCF/c-kit Ligand (25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse SCF/c-kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA). The ND₅₀ is typically 0.3-0.6 µg/mL." class="big_thumb" />

455-MC) was serially diluted and captured by Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox"> 455-MC) was serially diluted and captured by Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

455-MC) was serially diluted and captured by Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox"> 455-MC) was serially diluted and captured by Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-455-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

255-SC) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human SCF/c-kit Ligand (10 ng/mL) is neutralized (green line) by increasing concentrations of Human SCF/c-kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA). The ND₅₀ is typically 0.05-0.3 µg/mL." class="big_lightbox"> 255-SC) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human SCF/c-kit Ligand (10 ng/mL) is neutralized (green line) by increasing concentrations of Human SCF/c-kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA). The ND₅₀ is typically 0.05-0.3 µg/mL." alt="Recombinant Human SCF/c-kit Ligand (255-SC) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human SCF/c-kit Ligand (10 ng/mL) is neutralized (green line) by increasing concentrations of Human SCF/c-kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA). The ND₅₀ is typically 0.05-0.3 µg/mL." class="big_thumb" />

NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox"> NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

255-SC) was serially diluted and captured by Mouse Anti-Human SCF/c‑kit Ligand Monoclonal Antibody (Catalog # MAB655) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox"> 255-SC) was serially diluted and captured by Mouse Anti-Human SCF/c‑kit Ligand Monoclonal Antibody (Catalog # MAB655) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

255-SC) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human SCF/c-kit Ligand (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human SCF/c-kit Ligand Polyclonal Antibody (Catalog # AB-255-NA). The ND₅₀ is typically 0.4-2 µg/mL." class="big_lightbox"> 255-SC) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human SCF/c-kit Ligand (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human SCF/c-kit Ligand Polyclonal Antibody (Catalog # AB-255-NA). The ND₅₀ is typically 0.4-2 µg/mL." alt="Recombinant Human SCF/c-kit Ligand (Catalog # 255-SC) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human SCF/c-kit Ligand (10 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human SCF/c-kit Ligand Polyclonal Antibody (Catalog # AB-255-NA). The ND₅₀ is typically 0.4-2 µg/mL." class="big_thumb" />

255-SC) was serially diluted and captured by Mouse Anti-Human SCF/c‑kit Ligand Monoclonal Antibody (Catalog # MAB655) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox"> 255-SC) was serially diluted and captured by Mouse Anti-Human SCF/c‑kit Ligand Monoclonal Antibody (Catalog # MAB655) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" alt="Recombinant Human SCF/c‑kit Ligand (Catalog # 255-SC) was serially diluted and captured by Mouse Anti-Human SCF/c‑kit Ligand Monoclonal Antibody (Catalog # MAB655) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human SCF/c‑kit Ligand Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-255-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_thumb" />

BT-SCF-GMP), Animal-Free (BT-SCF-AFL) and RUO (Catalog # BT-SCF) grades of Recombinant Human SCF as measured in a cell proliferation assay using TF-1 human erythroleukemic cells (orange, green, red, respectively)." class="big_lightbox"> BT-SCF-GMP), Animal-Free (BT-SCF-AFL) and RUO (Catalog # BT-SCF) grades of Recombinant Human SCF as measured in a cell proliferation assay using TF-1 human erythroleukemic cells (orange, green, red, respectively)." class="big_thumb" />

BT-SCF-AFL) grades of Recombinant Human SCF as measured in a cell proliferation assay using TF-1 human erythroleukemic cells (orange and green, respectively)." class="big_lightbox"> BT-SCF-AFL) grades of Recombinant Human SCF as measured in a cell proliferation assay using TF-1 human erythroleukemic cells (orange and green, respectively)." class="big_thumb" />

BT-TPO-GMP, 100 ng/mL), FLT-3L (BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog # 7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 95% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog # MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=3 technical replicates is shown." class="big_lightbox"> BT-TPO-GMP, 100 ng/mL), FLT-3L (BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog # 7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 95% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog # MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=3 technical replicates is shown." class="big_thumb" />

BT-TPO-GMP, 100 ng/mL), FLT-3L (Catalog # BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog # 7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 90% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog # MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=4 technical replicates is shown." class="big_lightbox"> BT-TPO-GMP, 100 ng/mL), FLT-3L (Catalog # BT-FT3L-GMP, 100 ng/mL), and SR1 (Catalog # 7086, 1 µM). After 7 days, fold expansion was calculated from total viable cell counts. Cell viability on Day 7 was greater than 90% for all conditions. Frequency (%) CD34+ cells was analyzed by flow cytometry on Day 0 and Day 7 with an anti-human CD34 monoclonal antibody (Catalog # MAB7227). CD34+ cell expansion was calculated by multiplying total nucleated cell (TNC) fold expansion by the CD34+ percentage. The average fold expansion of n=4 technical replicates is shown." class="big_thumb" />